Cynthia M. Hardman
51 IP cases indexed. Covers patent matters.
Cases Presided Over
51 cases indexed | Page 2 of 2
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect Operating lost its IPR challenge against Align Technology regarding dental treatment planning technology. The PTAB ruled that the claimed obviousness over prior art was not demonstrated, upholding the validity of the patent claims.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect Operating lost its IPR challenge against Align Technology's '879 patent in a PTAB decision focused on obviousness. The Board rejected the petitioner’s argument that combining prior art references would render the claims obvious, upholding the validity of the challenged technology in orthodontics.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect Operating challenged Align Technology's dental treatment planning patent (11,369,456 B2) before the PTAB. The Board found a reasonable likelihood of prevailing on Ground 1, based on obviousness over Chishti-511, Chishti-876, and Sachdeva.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect Operating successfully moved its IPR against Align Technology's dental scanning patent to the trial phase. The Board found a reasonable likelihood of prevailing on at least one claim, leading to institution on all 20 claims.
Ascentcare Dental Products, Inc. v.Solmetex, LLC
The PTAB denied Ascentcare Dental Products' IPR petition against Solmetex, LLC's dental device patent due to procedural timing issues. The Board found the patent was a post-AIA patent and the petition was filed too early.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom and Abbott Diabetes Care settled their IPR dispute over U.S. Patent 11,298,056 covering continuous glucose monitoring technology. The parties filed a joint motion to terminate, and the Board granted termination without a final written decision.
LCY Biotechnology Holding, Inc. v.Radici Chimica, S.p.A.
LCY Biotechnology and Radici Chimica settled their post‑grant review dispute over U.S. Patent 11,781,148. The parties filed a joint motion to terminate, and the PTAB dismissed the petition, terminating the proceeding.
ETN CAPITAL, LLC d/b/a BEECH LANE v.FBA Operating Co.
The PTAB institution decision found that the Petitioner had a reasonable likelihood of prevailing on all asserted grounds (Grounds 1-6). The patent, related to vehicle leveling systems using smart devices, was deemed potentially invalid based on obviousness (35 U.S.C. § 103) when combining prior art references like Thorpe and Clark.
Eunsung Global Corp. v.HydraFacial LLC et al.
The PTAB denied institution for an IPR challenge regarding skin treatment systems due to substantial overlap with parallel ITC proceedings and advanced litigation. This decision emphasizes resource conservation when multiple venues address the same prior art.
Sinclair Pharma Limited et al. v.HydraFacial LLC
Sinclair Pharma Limited et al. successfully instituted IPR proceedings against HydraFacial LLC regarding skin treatment systems, finding a reasonable likelihood of obviousness over prior art references. The Board found that combining existing microdermabrasion and irrigation technologies renders the challenged claims unpatentable.
ResMed Corp. v.Cleveland Medical Devices, Inc.
The PTAB denied ResMed Corp.'s Inter Partes Review petition against Cleveland Medical Devices' patent, citing prior filings and concerns over 'road-mapping'.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed Corp. successfully convinced the PTAB to institute IPR proceedings against Cleveland Medical Devices, Inc.'s patent (No. 11690512). The Board found that ResMed demonstrated a reasonable likelihood of prevailing on Ground 1, allowing the challenge to proceed despite neutral merits.
ResMed Corp. v.Cleveland Medical Devices, Inc.
ResMed Corp. successfully petitioned for institution of its IPR against Cleveland Medical Devices, Inc.'s patent covering CPAP systems. The Board declined discretionary denial, finding that the petitioner adequately demonstrated a reasonable likelihood of prevailing on both 102 and 103 grounds.
ResMed Corp. v.Cleveland Medical Devices, Inc.
The PTAB granted institution for ResMed Corp.'s IPR against Cleveland Medical Devices, Inc., finding a reasonable likelihood of prevailing. The Board overcame arguments regarding parallel District Court litigation by applying the Fintiv factors.
LifeVac, LLC v.DCStar Inc.
LifeVac, LLC's IPR petition against DCStar Inc. was denied by the PTAB after the Board found insufficient evidence of unpatentability. The decision hinged on a prior art challenge regarding an inventor-originated public disclosure (IDEAR) that predated one key reference.
MPL Brands NV, Inc. v.BuzzBallz, LLC
MPL Brands NV successfully petitioned for institution of its obviousness challenge against BuzzBallz's beverage container patent (11932441). The Board found that the design application introduced new matter, making the claims eligible for review.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent on modified PH20 polypeptides in a PGR proceeding. The Board found likelihood of prevailing based on arguments regarding the genus's scope and potential lack of enablement/obviousness.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB to challenge Halozyme's PH20 polypeptide claims under 35 U.S.C. § 112 for lack of written description and enablement. The Board instituted the petition, finding that the specification broadly defines a 'modified PH20 polypeptide' but lacked sufficient examples to support the vast scope of multiply-substituted variants claimed.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB to invalidate Halozyme, Inc.'s claims covering a genus of modified PH20 polypeptides. The Board found that the broad scope of the claimed variants lacked adequate written description and enablement support in the original patent disclosure. This decision significantly challenges the breadth of the patented technology in hyaluronidase drug development.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned to institute IPR against Halozyme, Inc.'s patent (12195773) based on grounds of enablement and obviousness. The Board found it likely that the claims defining a vast genus of modified polypeptides are unpatentable due to insufficient disclosure regarding solubility and activity prediction.
Eunsung Global Corp. v.HydraFacial LLC et al.
Eunsung Global Corp. and HydraFacial LLC settled their inter partes review disputes, leading the PTAB to terminate both IPRs before institution. The settlement agreement is treated as confidential business information.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.